Effective with the date of service of April 30, 2018, the North Carolina Medicaid and Health Choice programs will be terminating Clinical Policy 1B-3, Intravenous Iron Therapy, within the Physician Drug Program.
Topics Related to Doctors (DO, DC, MD and DPM)
Effective with the date of service of April 30, 2018, the North Carolina Medicaid and N.C. Health Choice programs will be terminating Clinical Policy 1B-3, Intravenous Iron Therapy, within the Physician Drug Program.
Effective with the date of service of April 30, 2018, the North Carolina Medicaid and N.C. Health Choice programs will be terminating Clinical Policy 1B-3, Intravenous Iron Therapy, within the Physician Drug Program.
Effective with date of service Oct. 23, 2017, the N.C. Medicaid and N.C. Health Choice (NCHC) programs cover meropenem and vaborbactam for injection, for intravenous use (Vabomere) for use in the Physician's Drug Program (PDP) when billed with HCPCS code J3490 - Unclassified drugs.
Effective with date of service Oct. 15, 2017, the NC Medicaid Program covers triamcinolone acetonide extended-release injectable suspension, for intra-articular use (Zilretta) for use in the Physician’s Drug Program (PDP) when billed with HCPCS code J3490 - Unclassified drugs.